Q2 2024 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2024-08-14 · accession 0001583977-24-000003
$1.73B
Reported value
49
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $373.5M | 21.6% | 8,494,151 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $91.6M | 5.29% | 2,025,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $84.2M | 4.86% | 1,525,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $83.1M | 4.80% | 1,100,000 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $75.4M | 4.36% | 2,790,462 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $72.4M | 4.18% | 8,325,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $68.4M | 3.95% | 2,940,283 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $60.5M | 3.49% | 1,350,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $54.1M | 3.13% | 3,006,534 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $49.7M | 2.87% | 840,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $47.1M | 2.72% | 1,858,351 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $45.2M | 2.61% | 675,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $44.2M | 2.55% | 2,300,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $44.0M | 2.54% | 1,050,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $32.2M | 1.86% | 400,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $30.8M | 1.78% | 975,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $29.7M | 1.72% | 2,909,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $28.6M | 1.65% | 2,147,400 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $28.3M | 1.64% | 685,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $28.2M | 1.63% | 2,130,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $27.8M | 1.61% | 801,963 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $27.7M | 1.60% | 1,650,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $27.6M | 1.59% | 1,466,460 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $23.5M | 1.36% | 2,525,000 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $19.8M | 1.14% | 125,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $19.6M | 1.13% | 1,125,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $19.5M | 1.13% | 475,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $19.4M | 1.12% | 1,182,563 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $17.5M | 1.01% | 1,450,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $17.4M | 1.00% | 425,000 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $16.1M | 0.93% | 3,570,872 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $14.6M | 0.84% | 1,611,600 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $13.6M | 0.79% | 500,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $11.9M | 0.69% | 625,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $9.6M | 0.55% | 515,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $9.4M | 0.54% | 1,000,000 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $9.0M | 0.52% | 265,826 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $8.6M | 0.50% | 245,000 | Common | SOLE |
| 45256X103 | IBRX | IMMUNITYBIO INC | $7.9M | 0.46% | 1,250,000 | PUT | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $6.9M | 0.40% | 593,043 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $6.0M | 0.35% | 75,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $5.8M | 0.33% | 427,163 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $5.2M | 0.30% | 2,600,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $3.9M | 0.23% | 107,344 | Common | SOLE |
| 826917106 | SIGA | SIGA TECHNOLOGIES INC | $3.8M | 0.22% | 500,000 | PUT | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $2.7M | 0.16% | 1,394,336 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $2.0M | 0.12% | 2,030,823 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $1.7M | 0.10% | 350,000 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $1.5M | 0.09% | 496,750 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.